Nobivac FeLV, Suspension for Injection for Cats

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Feline leukemia virus

Available from:

Virbac

ATC code:

QI06AA01

INN (International Name):

Feline leukemia virus

Pharmaceutical form:

Suspension for injection

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Cats

Therapeutic area:

Inactivated Viral Vaccine

Authorization status:

Authorized

Authorization date:

2005-10-28

Summary of Product characteristics

Revised: August 2023
AN: 00190/2023
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCT
Nobivac FeLV Suspension for Injection for Cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Per dose of 1 ml:
ACTIVE SUBSTANCE
Minimum quantity of purified p45 FeLV-envelope antigen
102 µg
ADJUVANTS
3 % aluminium hydroxide gel expressed as mg Al
3+
1 mg
Purified extract of _Quillaja saponaria_
10 µg
EXCIPIENT
Buffered isotonic solution
to 1 ml
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Suspension for injection.
Opalescent liquid.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES

For active immunisation of healthy cats to prevent persistent feline
leukaemia-virus
viraemia and any associated clinical signs of the feline leucosis.

The onset of protection begins 2 weeks after immunisation and the
duration of
protection lasts one year after the primo-vaccination.

Following a first booster vaccination one year after the primary
vaccination course, a
duration of immunity of 3 years has been demonstrated.
4.3
CONTRA-INDICATIONS
None.
Revised: August 2023
AN: 00190/2023
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
It is recommended that animals be treated for intestinal parasites at
least 10 days prior
to vaccination.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO ANIMALS
In the case of accidental self-injection, seek medical advice
immediately and show the
package leaflet or the label to the physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Transient and small thickening or nodule, approximately 5 - 10 mm in
size, may be
observed at the injection site and disappear within 2 to 6 weeks
without treatment.
Occasionally, systemic reactions (hyperthermia, anorexia, lethargy)
may occur within
one or two days after vaccine ad